pharma

Hedge funds are steering clear of the booming artificial intelligence (AI) market and other technology stocks that have led the market rally over the past year. Instead, they are placing their bets on the healthcare sector, revealing a calculated move towards stability and value. According to the...

With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned to fighting cancer, the one battle that pharma never seems to win. Moderna ended 2023 by...

Last Thursday, Johnson & Johnson (NASDAQ: JNJ) has topped earnings estimates and uplifted its full-year guidance on the back of a strong medtech sales momentum. The healthcare conglomerate reported strong results with plenty of legal anxiety in the air owed to thousands of lawsuits claiming its...

By Lisa Om, VP of product marketing at USDM Life Sciences The pandemic hit life science companies hard, and just as they started to stabilize, a new wave of macroeconomic challenges is crushing the industry. Threats of a looming recession make funding hard to come by, and along with high...

In a recent report, Bank of America identified the “Disruptive Dozen” emerging technologies that have the most potential to disrupt and revolutionize the healthcare sector over the next years. New therapy for ALS (amyotrophic lateral sclerosis) and a blood test for Alzheimer’s...

Key Takeaways: Burning Rock’s net loss narrowed 29% to 185 million yuan in the first quarter from the same period a year earlier, helped by lower R&D and sales expenses Revenues from R&D services for drug companies more than doubled, becoming the company’s latest growth engine...

As markets continue to witness bouts of volatility led by economic data, Federal Reserve officials' remarks and inflation expectations, some investors continue to prefer buying and holding on to dividend-paying stocks that boast a higher yield. Let's take a look at some interesting stocks that will...

If you’re reading this, then apparently you weren’t affected by a global internet outage that hit many news websites. The outage appeared to hurt stock futures overnight, but things recovered to flat in the hours right before the open.  Flat might be the word of the day, and maybe...

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares came under pressure Monday after the Food and Drug Administration (FDA) rejected its regulatory application seeking label expansion for its dementia drug. The Acadia Analysts: Goldman Sachs analyst Salveen Richter downgraded Acadia shares...

A biotech with licensing agreements with some of the big-name pharma companies such as AbbVie Inc (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ)'s Janssen unit is testing the IPO waters this week. IPO Terms Waltham, Massachusetts-based Morphic Holding is offering 5 million shares in an IPO...

The week will see the listing of a late entrant into the arena, but it nonetheless has an impressive pipeline of investigational assets targeting genetic diseases. The IPO Terms BridgeBio Pharma (NASDAQ: BBIO),founded in 2015 and headquartered in Palo Alto, California, is set to offer 15 million...

Versum Materials (NYSE: VSM) has approved a "superior" buyout proposal from MERCK KGAA/S ADR (OTC: MKKGY) at $53 per share after backing out of a previously announced merger with Entegris Inc (NASDAQ: ENTG). What Happened The business combination received unanimous...

Veeva Systems Inc (NYSE: VEEV), a cloud-computing company focused on the pharma and life sciences industry, is an underpriced asset within the broader SaaS universe, according to Morgan Stanley.  The Analyst Morgan Stanley analyst Stan Zlotsky upgraded Veeva Systems from Equal-weight to...

Radius Health Inc (NASDAQ: RDUS) has multiple catalysts that could drive near-term upside in the shares of the company, according to Morgan Stanley.  Radius Health is an integrated biopharma company that specializes in therapies for osteoporosis, oncology and endocrine diseases. The Analyst...

Allergan plc Ordinary Shares (NYSE: AGN) is down 26 percent over the last six months, but one analyst said there's only upside to its sickly state. The biotech’s trajectory inspired an upgrade from a three-year Hold. The Rating Barclays analyst Douglas Tsao upgraded Allergan to a Buy...